<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5879">
  <stage>Registered</stage>
  <submitdate>30/09/2015</submitdate>
  <approvaldate>30/09/2015</approvaldate>
  <nctid>NCT02580877</nctid>
  <trial_identification>
    <studytitle>Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)</studytitle>
    <scientifictitle>Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Oral Insulin-TN20</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 67.5 mg oral insulin crystals daily
Treatment: drugs - 500mg oral insulin crystals every other week

Experimental: 67.5 mg oral insulin crystals daily - 67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months

Experimental: 500mg oral insulin crystals every other week - 500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months


Treatment: drugs: 67.5 mg oral insulin crystals daily
human insulin crystals in capsules

Treatment: drugs: 500mg oral insulin crystals every other week
human insulin crystals in capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Immune Function - Assessed by level or quality of T-lymphocyte or autoantibody biomarkers of beta cell specific immune response as measured by change in: CD4 auto-antigen specific ELISPOTs for IFN-g and IL-17, and cD8 peptide-HLA multimers (Q-dots).</outcome>
      <timepoint>13 and 26 weeks after first dose versus baseline</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participants in TrialNet Natural History/Pathway to Prevention Study (TN01); is
             relative of proband with type 1 diabetes

          -  Between ages 3-45 with normal Oral Glucose Tolerance Test (OGTT) or between ages 3-7
             with an abnormal OGTT

          -  Confirmed positive for insulin autoantibodies within previous six months

          -  Confirmed positive for one or more other autoantibodies on two separate occasions
             within the past six months</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosed with type 1 diabetes

          -  History of treatment with insulin or oral hypoglycemic agent

          -  History of therapy with immunosuppressive drugs or non-physiologic glucocorticoids
             within the past two years for a period of more than three months

          -  Ongoing use of medications known to influence glucose tolerance

          -  Pregnant or intending to become pregnant while on study or lactating</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>92</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Walter and Eliza Hall Institute of Medical Research - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Type 1 Diabetes TrialNet</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to
      assess the effects of varying doses and schedules of oral insulin on immunological and
      metabolic markers in relatives at risk for type 1 diabetes (T1D).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02580877</trialwebsite>
    <publication>Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005 May;28(5):1068-76.
Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, Theil A, Eugster A, Puff R, Peplow C, Buettner F, Lange K, Hasford J, Achenbach P; Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015 Apr 21;313(15):1541-9. doi: 10.1001/jama.2015.2928.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Carla Greenbaum, MD</name>
      <address>Type 1 Diabetes TrialNet</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>